Chronic kidney disease (CKD)
Hyperuricemia and gout have been important diseases, which have close relationship with metabolic syndrome, cardiovascular, and chronic kidney diseases. Oral medicine for treatment includes febuxostat and allopurinol. Both agents have been compared as urate-lowering therapy for the influence of cardiovascular and renal risk factors. Some papers showed no difference for the major adverse cardiac events (MACEs) between both agents. However, there have been controversies concerning the benefit and risk of them. Further evaluation would be necessary and expected for future research.
Journal of Diabetes, Obesity & Metabolism
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(https://creativecommons.org/licenses/by-nc-sa/4.0/).
|URL ( Publisher's Version )|
jdom_3_1_e104.pdf 348 KB